Red Blood Cell Alloimmunization in the Pregnant Patient

Heddle, 1995, A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion, Br J Haematol, 91, 1000, 10.1111/j.1365-2141.1995.tb05425.x Redman, 1996, A prospective study of the incidence of red cell Allo-immunisation following transfusion, Vox Sang, 71, 216, 10.1159/000462061 Schonewille, 2006, Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures?, Transfusion, 46, 630, 10.1111/j.1537-2995.2006.00764.x Schonewille, 2016, Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study), Transfusion, 56, 311, 10.1111/trf.13347 White, 2016, British Committee for Standards in Haematology. Guideline for blood grouping and red cell antibody testing in pregnancy, Transfus Med, 26, 246, 10.1111/tme.12299 Gottvall, 2008, Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden, Acta Obstet Gynecol Scand, 87, 843, 10.1080/00016340802268880 2018, Obstet Gynecol, 131, e82, 10.1097/AOG.0000000000002528 Koelewijn, 2008, Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands, Transfusion, 48, 941, 10.1111/j.1537-2995.2007.01625.x American Association of Blood Banks, 2017 Reid, 2012 Hendrickson, 2016, Hemolytic disease of the fetus and newborn: modern practice and future investigations, Transfus Med Rev, 30, 159, 10.1016/j.tmrv.2016.05.008 B.-O. Committee on Practice, 2017, Practice bulletin no. 181: prevention of Rh D Alloimmunization, Obstet Gynecol, 130, e57, 10.1097/AOG.0000000000002232 Andersen, 2002, Prognostic value of screening for irregular antibodies late in pregnancy in rhesus positive women, Acta Obstet Gynecol Scand, 81, 407, 10.1034/j.1600-0412.2002.810506.x Rothenberg, 1999, Is a third-trimester antibody screen in Rh+ women necessary?, Am J Manag Care, 5, 1145 Adeniji, 2007, Should we continue screening rhesus D positive women for the development of atypical antibodies in late pregnancy?, J Matern Fetal Neonatal Med, 20, 59, 10.1080/14767050601123317 Slootweg, 2016, Third trimester screening for alloimmunisation in Rhc-negative pregnant women: evaluation of the Dutch national screening programme, BJOG, 123, 955, 10.1111/1471-0528.13816 Dajak, 2011, Severe hemolytic disease of fetus and newborn caused by red blood cell antibodies undetected at first-trimester screening (CME), Transfusion, 51, 1380, 10.1111/j.1537-2995.2010.03006.x Geifman-Holtzman, 1997, Female alloimmunization with antibodies known to cause hemolytic disease, Obstet Gynecol, 89, 272, 10.1016/S0029-7844(96)00434-6 Geaghan, 2011, Diagnostic laboratory technologies for the fetus and neonate with isoimmunization, Semin Perinatol, 35, 148, 10.1053/j.semperi.2011.02.009 Mbalibulha, 2015, Occurrence of anti-D alloantibodies among pregnant women in Kasese District, western Uganda, J Blood Med, 6, 125, 10.2147/JBM.S80977 Natukunda, 2011, Maternal red blood cell alloimmunisation in south western Uganda, Transfus Med, 21, 262, 10.1111/j.1365-3148.2011.01073.x Osaro, 2010, Rh isoimmunization in sub-Saharan Africa indicates need for universal access to anti-RhD immunoglobulin and effective management of D-negative pregnancies, Int J Womens Health, 2, 429, 10.2147/IJWH.S15165 Zipursky, 2015, Rhesus disease: a major public health problem, Lancet, 386, 651, 10.1016/S0140-6736(15)61498-2 Zipursky, 2011, The global burden of Rh disease, Arch Dis Child Fetal Neonatal Ed, 96, F84, 10.1136/adc.2009.181172 Koelewijn, 2009, Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy, BJOG, 116, 655, 10.1111/j.1471-0528.2008.01984.x Koelewijn, 2009, Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis, BJOG, 116, 1307, 10.1111/j.1471-0528.2009.02244.x Schonewille, 2006, Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity, Transfusion, 46, 250, 10.1111/j.1537-2995.2006.00708.x Verduin, 2015, Female sex of older patients is an independent risk factor for red blood cell alloimmunization after transfusion, Transfusion, 55, 1478, 10.1111/trf.13111 Verduin, 2012, Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review, Transfus Med Rev, 26, 342, 10.1016/j.tmrv.2011.12.001 Schonewille, 2014, HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies, Transfusion, 54, 1971, 10.1111/trf.12624 Verduin, 2016, The HLA-DRB1*15 phenotype is associated with multiple red blood cell and HLA antibody responsiveness, Transfusion, 56, 1849, 10.1111/trf.13648 Ryder, 2014, Factors influencing RBC Alloimmunization: lessons learned from murine models, Transfus Med Hemother, 41, 406, 10.1159/000368995 Zimring, 2012, Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: current paradigms and future considerations, Transfus Clin Biol, 19, 125, 10.1016/j.tracli.2012.03.002 Hendrickson, 2010, Storage of murine red blood cells enhances alloantibody responses to an erythroid-specific model antigen, Transfusion, 50, 642, 10.1111/j.1537-2995.2009.02481.x Hendrickson, 2011, Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity, Transfusion, 51, 2445, 10.1111/j.1537-2995.2011.03162.x Hendrickson, 2007, Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells, Blood, 110, 2736, 10.1182/blood-2007-03-083105 Zimring, 2008, The role of inflammation in alloimmunization to antigens on transfused red blood cells, Curr Opin Hematol, 15, 631, 10.1097/MOH.0b013e328313695e Stowell, 2013, Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model, Blood, 122, 1494, 10.1182/blood-2013-03-488874 Cruz-Leal, 2017, Prevention of hemolytic disease of the fetus and newborn: what have we learned from animal models?, Curr Opin Hematol, 24, 536, 10.1097/MOH.0000000000000374 Geaghan, 2011, Fetal health assessment in utero by laboratory technologies: clinical benefits, risks and controversies, Clin Biochem, 44, 460, 10.1016/j.clinbiochem.2011.03.015 Geaghan, 2012, Fetal laboratory medicine: on the frontier of maternal-fetal medicine, Clin Chem, 58, 337, 10.1373/clinchem.2011.166991 Stetson, 2017, Anti-M alloimmunization: management and outcome at a single institution, AJP Rep, 7, e205, 10.1055/s-0037-1607028 Dubey, 2015, Comparative evaluation of gel column agglutination and erythrocyte magnetized technology for red blood cell alloantibody titration, Immunohematology, 31, 1, 10.21307/immunohematology-2019-063 Finck, 2013, Comparison of a gel microcolumn assay with the conventional tube test for red blood cell alloantibody titration, Transfusion, 53, 811, 10.1111/j.1537-2995.2012.03793.x Bachegowda, 2017, Impact of uniform methods on Interlaboratory antibody titration variability: antibody titration and uniform methods, Arch Pathol Lab Med, 141, 131, 10.5858/arpa.2015-0351-OA Kapur, 2014, Low anti-RhD IgG-fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn, Br J Haematol, 166, 936, 10.1111/bjh.12965 Sonneveld, 2017, Antigen specificity determines anti-red blood cell IgG-fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn, Br J Haematol, 176, 651, 10.1111/bjh.14438 p.s.o. Society for Maternal-Fetal Medicine, 2015, Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia—diagnosis and management, Am J Obstet Gynecol, 212, 697, 10.1016/j.ajog.2015.01.059 Bills, 2014, Fetal blood grouping using cell free DNA—an improved service for RhD negative pregnant women, Transfus Apher Sci, 50, 148, 10.1016/j.transci.2014.02.005 Clausen, 2014, Noninvasive fetal RhD genotyping, Transfus Apher Sci, 50, 154, 10.1016/j.transci.2014.02.008 Finning, 2008, Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study, BMJ, 336, 816, 10.1136/bmj.39518.463206.25 Clausen, 2014, Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark, Prenat Diagn, 34, 1000, 10.1002/pd.4419 Haimila, 2017, Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland, Acta Obstet Gynecol Scand, 96, 1228, 10.1111/aogs.13191 Norweigan Directorate of Health de Haas, 2016, Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands, BMJ, 355 Daniels, 2018, Vox Sanguinis international forum on application of fetal blood grouping, Vox Sang, 113, e26, 10.1111/vox.12615 National Institute for Health and Care Excellence (NICE) Finning, 2007, Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma, Transfusion, 47, 2126, 10.1111/j.1537-2995.2007.01437.x Moise, 2016, Circulating cell-free DNA to determine the fetal RHD status in all three trimesters of pregnancy, Obstet Gynecol, 128, 1340, 10.1097/AOG.0000000000001741 van der Schoot, 2017, Genotyping to prevent Rh disease: has the time come?, Curr Opin Hematol, 24, 544, 10.1097/MOH.0000000000000379 Bevis, 1953, The composition of liquor amnii in haemolytic disease of the newborn, J Obstet Gynaecol Br Emp, 60, 244, 10.1111/j.1471-0528.1953.tb07683.x Liley, 1961, Liquor amnil analysis in the management of the pregnancy complicated by resus sensitization, Am J Obstet Gynecol, 82, 1359, 10.1016/S0002-9378(16)36265-2 Bowman, 1965, Amniotic fluid spectrophotometry and early delivery in the Management of Erythroblastosis Fetalis, Pediatrics, 35, 815, 10.1542/peds.35.5.815 Queenan, 1993, Deviation in amniotic fluid optical density at a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks' gestation: a proposal for clinical management, Am J Obstet Gynecol, 168, 1370, 10.1016/S0002-9378(11)90767-4 Mari, 2000, Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the blood velocity in anemic fetuses, N Engl J Med, 342, 9, 10.1056/NEJM200001063420102 Mari, 2002, Accurate prediction of fetal hemoglobin by Doppler ultrasonography, Obstet Gynecol, 99, 589 Mari, 2008, Fetal Doppler: umbilical artery, middle cerebral artery, and venous system, Semin Perinatol, 32, 253, 10.1053/j.semperi.2008.04.007 Oepkes, 2006, Doppler ultrasonography versus amniocentesis to predict fetal anemia, N Engl J Med, 355, 156, 10.1056/NEJMoa052855 Zimmerman, 2002, Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat, BJOG, 109, 746, 10.1111/j.1471-0528.2002.01314.x Moise, 2008, The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia, Am J Obstet Gynecol, 198, 161, 10.1016/j.ajog.2007.10.788 Moise, 2012, Management and prevention of red cell alloimmunization in pregnancy: a systematic review, Obstet Gynecol, 120, 1132, 10.1097/AOG.0b013e31826d7dc1 Deka, 2016, Perinatal survival and procedure-related complications after intrauterine transfusion for red cell alloimmunization, Arch Gynecol Obstet, 293, 967, 10.1007/s00404-015-3915-7 van Kamp, 2004, Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988-1999, Acta Obstet Gynecol Scand, 83, 731, 10.1111/j.0001-6349.2004.00394.x Lindenburg, 2014, Intrauterine blood transfusion: current indications and associated risks, Fetal Diagn Ther, 36, 263, 10.1159/000362812 Kumar, 2005, Management of pregnancies with RhD alloimmunisation, BMJ, 330, 1255, 10.1136/bmj.330.7502.1255 Connan, 2009, IVIG - is it the answer? Maternal administration of immunoglobulin for severe fetal red blood cell alloimmunisation during pregnancy: a case series, Aust N Z J Obstet Gynaecol, 49, 612, 10.1111/j.1479-828X.2009.01091.x Fox, 2008, Early intraperitoneal transfusion and adjuvant maternal immunoglobulin therapy in the treatment of severe red cell alloimmunization prior to fetal intravascular transfusion, Fetal Diagn Ther, 23, 159, 10.1159/000111599 Deka, 1996, Intravenous immunoglobulin as primary therapy or adjuvant therapy to intrauterine fetal blood transfusion: a new approach in the management of severe Rh-immunization, J Obstet Gynaecol Res, 22, 561, 10.1111/j.1447-0756.1996.tb01071.x Voto, 1997, High-dose gammaglobulin (IVIG) followed by intrauterine transfusions (IUTs): a new alternative for the treatment of severe fetal hemolytic disease, J Perinat Med, 25, 85, 10.1515/jpme.1997.25.1.85 Schwartz, 2016, Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for apheresis: the seventh special issue, J Clin Apher, 31, 149 Nwogu, 2018, Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion, Transfusion, 58, 677, 10.1111/trf.14453 Fernandez Alba, 2014, Treatment of D alloimmunization in pregnancy with plasmapheresis and intravenous immune globulin: case report, Transfus Apher Sci, 51, 70, 10.1016/j.transci.2014.02.026 Houston, 2015, Severe Rh alloimmunization and hemolytic disease of the fetus managed with plasmapheresis, intravenous immunoglobulin and intrauterine transfusion: a case report, Transfus Apher Sci, 53, 399, 10.1016/j.transci.2015.07.010 Isojima, 2011, Early plasmapheresis followed by high-dose gamma-globulin treatment saved a severely rho-incompatible pregnancy, J Clin Apher, 26, 216, 10.1002/jca.20288 Ruma, 2007, Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization, Am J Obstet Gynecol, 196, 138.e131, 10.1016/j.ajog.2006.10.890 Palfi, 2006, A case of severe Rh (D) alloimmunization treated by intensive plasma exchange and high-dose intravenous immunoglobulin, Transfus Apher Sci, 35, 131, 10.1016/j.transci.2006.07.002 Adam, 2016, Autologous intrauterine transfusion in a case of anti-U, Transfusion, 56, 3029, 10.1111/trf.13806 Lydaki, 2005, Serial blood donations for intrauterine transfusions of severe hemolytic disease of the newborn with the use of recombinant erythropoietin in a pregnant woman alloimmunized with anti-Ku, Transfusion, 45, 1791, 10.1111/j.1537-2995.2005.00604.x Al Riyami, 2014, Successful management of severe hemolytic disease of the fetus due to anti-Jsb using intrauterine transfusions with serial maternal blood donations: a case report and a review of the literature, Transfusion, 54, 238, 10.1111/trf.12331 Santolaya-Forgas, 1999, Use of recombinant human erythropoietin (EPO-alfa) in a mother alloimmunized to the Js(b) antigen, J Matern Fetal Med, 8, 141, 10.1002/(SICI)1520-6661(199905/06)8:3<141::AID-MFM14>3.0.CO;2-K Delaney, 2017, Blood group antigen matching influence on gestational outcomes (AMIGO) study, Transfusion, 57, 525, 10.1111/trf.13977 Goldman, 2015, The prevalence of anti-K in Canadian prenatal patients, Transfusion, 55, 1486, 10.1111/trf.13151 O'Brien, 2015, Provision of KEL1-negative blood to obstetric patients: a 3-year single-institution retrospective review, Transfusion, 55, 599, 10.1111/trf.12814 Osaro, 2015, Distribution of Kell phenotype among pregnant women in Sokoto, north western Nigeria, Pan Afr Med J, 21, 301, 10.11604/pamj.2015.21.301.4636 Aygun, 2002, Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions, Transfusion, 42, 37, 10.1046/j.1537-2995.2002.00007.x Chou, 2013, High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors, Blood, 122, 1062, 10.1182/blood-2013-03-490623 Miller, 2013, Red blood cell alloimmunization in sickle cell disease: prevalence in 2010, Transfusion, 53, 704, 10.1111/j.1537-2995.2012.03796.x Svensson, 2015, Considerations of red blood cell molecular testing in transfusion medicine, Expert Rev Mol Diagn, 15, 1455, 10.1586/14737159.2015.1086646 Hendrickson, 2014, Red blood cell alloimmunization mitigation strategies, Transfus Med Rev, 28, 137, 10.1016/j.tmrv.2014.04.008 Gehrie, 2017, Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease, Transfusion, 57, 2267, 10.1111/trf.14212 Kacker, 2014, Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients, Transfusion, 54, 86, 10.1111/trf.12250 Stasi, 2010, Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura, Curr Opin Mol Ther, 12, 734 Yver, 2012, Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized fc for improved engagement of FCgammaRIII, in healthy volunteers, Vox Sang, 103, 213, 10.1111/j.1423-0410.2012.01603.x Karanth, 2013, Anti-D administration after spontaneous miscarriage for preventing rhesus alloimmunisation, Cochrane Database Syst Rev, 10.1002/14651858.CD009617.pub2 Fung, 2018, No. 133-prevention of Rh alloimmunization, J Obstet Gynaecol Can, 40, e1, 10.1016/j.jogc.2017.11.007 Branch, 2006, Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-beta and prostaglandin E2, Transfusion, 46, 1316, 10.1111/j.1537-2995.2006.00898.x Kapur, 2015, Prophylactic anti-D preparations display variable decreases in fc-fucosylation of anti-D, Transfusion, 55, 553, 10.1111/trf.12880 Bowman, 1987, Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures, Transfus Med Rev, 1, 101, 10.1016/S0887-7963(87)70010-8 Chilcott, 2003, A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative, Health Technol Assess, 7, iii, 10.3310/hta7040 Huchet, 1987, Ante-partum administration of preventive treatment of Rh-D immunization in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicenter study carried out in the Paris region, J Gynecol Obstet Biol Reprod (Paris), 16, 101 Jones, 2004, A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant, BJOG, 111, 892, 10.1111/j.1471-0528.2004.00243.x Bowman, 2003, Thirty-five years of Rh prophylaxis, Transfusion, 43, 1661, 10.1111/j.0041-1132.2003.00632.x de Haas, 2014, Anti-D prophylaxis: past, present and future, Transfus Med, 24, 1, 10.1111/tme.12099 Engelfriet, 2003, Current status of immunoprophylaxis with anti-D immunoglobin, Vox Sang, 85, 328 McBain, 2015, Anti-D administration in pregnancy for preventing rhesus alloimmunisation, Cochrane Database Syst Rev, 10.1002/14651858.CD000020.pub3 Welsh, 2016, Pathology consultation on patients with a large Rh immune globulin dose requirement, Am J Clin Pathol, 145, 744, 10.1093/ajcp/aqw051 Chen, 2002, Multicenter clinical experience with flow cytometric method for fetomaternal hemorrhage detection, Cytometry, 50, 285, 10.1002/cyto.10154 Farias, 2016, Flow cytometry in detection of fetal red blood cells and maternal F cells to identify Fetomaternal hemorrhage, Fetal Pediatr Pathol, 35, 385, 10.1080/15513815.2016.1209260 Chambers, 2012, Comparison of haemoglobin F detection by the acid elution test, flow cytometry and high-performance liquid chromatography in maternal blood samples analysed for fetomaternal haemorrhage, Transfus Med, 22, 199, 10.1111/j.1365-3148.2012.01143.x Dziegiel, 2006, Detecting fetomaternal hemorrhage by flow cytometry, Curr Opin Hematol, 13, 490, 10.1097/01.moh.0000245687.09215.c4 Kim, 2012, Detection of fetomaternal hemorrhage, Am J Hematol, 87, 417, 10.1002/ajh.22255 Pham, 2015, Rhesus immune globulin dosing in the obesity epidemic era, Arch Pathol Lab Med, 139, 1084, 10.5858/arpa.2014-0605-LE Woo, 2017, Rhesus immunoglobulin dosage and administration in obese individuals, Arch Pathol Lab Med, 141, 17, 10.5858/arpa.2016-0286-LE Wagner, 1999, Molecular basis of weak D phenotypes, Blood, 93, 385, 10.1182/blood.V93.1.385 Sandler, 2015, It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American pathologists transfusion medicine resource committee work group, Transfusion, 55, 680, 10.1111/trf.12941 Kacker, 2015, Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype, Transfusion, 55, 2095, 10.1111/trf.13074 Schonewille, 2007, High additional maternal red cell alloimmunization after rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus, Am J Obstet Gynecol, 196, 143, 10.1016/j.ajog.2006.10.895 Watson, 2006, Prevalence of new maternal alloantibodies after intrauterine transfusion for severe rhesus disease, Am J Perinatol, 23, 189, 10.1055/s-2006-934092 Schonewille, 2015, Extended matched intrauterine transfusions reduce maternal Duffy, Kidd, and S antibody formation, Transfusion, 55, 2912, 10.1111/trf.13231